Founded in 2014 by renowned clinician and PRP technology expert Dr. Mitra Najafi, Pplus Medical is a pioneering medical technology company dedicated to advancing regenerative medicine. With initial funding from Dr. Najafi and later support from third-party investors, the company has developed and patented a portfolio of groundbreaking innovations, including the PRP Digital Storage Device and the Collagen Related Peptide (CRP-A).
These products are built on the foundation of a peer-reviewed study conducted in collaboration with the hematology lab at St Thomas’ Hospital in London and published in the British Journal of Biomedical Science in 2017. The research demonstrated that platelet-rich plasma (PRP) can retain its regenerative properties for at least five days at room temperature.
Leveraging these insights, Pplus created the PRP Digital Storage Device, which extends PRP functionality for up to seven days with minimal loss of platelet activity. Complementing this is the CRP-A, a novel peptide designed to enhance platelet activation and improve therapeutic outcomes.
These innovations underscore our dedication to pioneering advancements that enhance patient outcomes and set new standards in medical technology.
Designed specifically for research and diagnostic applications, the DSD preserves platelet-rich plasma (PRP) functionality at room temperature for up to 7 days, eliminating the need for freezing or refrigeration and significantly reducing platelet activity loss.
The device gently agitates platelets to simulate their natural movement in the bloodstream, while its built-in battery allows for easy transport of samples without reliance on a main power supply.
With the DSD, researchers can:
✅ Maintain strong platelet activation and growth factor release
✅ Minimise delays and reduce waste from frequent fresh sample collection
✅ Keep PRP readily available for extended testing periods
This advancement supports more flexible and efficient workflows in PRP-related research and diagnostics.
We’re pleased to share that Sydney University recently presented a validation abstract of the DSD at the ISTH conference
CRP-A is currently utilized by some of the most prestigious laboratories and universities, including Cambridge and Oxford Universities in the UK, Harvard Medical School in the USA, Heart Research Institute (HRI) and the University of Sydney in Australia. Our peptide is used in fields such as hematology, cardiovascular research, thrombosis, drug discovery, drug delivery, platelet disorders, hemophilia, rare and chronic diseases, and many more.
✅ High purity (greater than 99%) and high dose response
✅ CRP-A is stable, scalable, and offers excellent batch-to-batch consistency
✅ Strong platelet agonist proven to form a triple helical structure and fully activate platelets via the Glycoprotein GPVI Receptor Pathway
✅ Full activity demonstrated with three different solvents
✅ 2 Year Shelf Life
Use this form to send us a message.
*All fields are required.
